Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.
Authors
Sun Young Rha
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea;
Sun Young Rha , Wilson H. Miller Jr., María José de Miguel , Seock-Ah Im , Iwona Lugowska , Martin Wermke , Daisuke Kotani , Todd Michael Bauer , Atsuo Takashima , John Palcza , Marya F. Chaney , Konstantin Dobrenkov , Elena Garralda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02720068
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 394)
DOI
10.1200/JCO.2023.41.4_suppl.394
Abstract #
394
Poster Bd #
G16
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF).
First Author: Ian Chau
Poster
2022 ASCO Annual Meeting
Phase 1 trial of first-line bintrafusp alfa in combination with other anticancer therapies in patients (pts) with locally advanced or advanced cervical cancer.
First Author: Ana Oaknin
Poster
2022 ASCO Annual Meeting
Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.
First Author: Nathalie A. Johnson
Poster
2021 ASCO Annual Meeting
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
First Author: Elena Garralda